Abbott Rx Business Reaches Maturity With Hospital Products Spin-Off Plan
Executive Summary
Abbott's spin-off of the hospital products business indicates that the company is confident it has emerged as a top-tier R&D-driven pharmaceutical company
You may also be interested in...
Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott Pharmaceutical Products Group President & COO Jeffrey Leiden's experience overseeing the Knoll acquisition could make the exec a particularly attractive candidate in the current climate of increasing M&A activity
Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott Pharmaceutical Products Group President & COO Jeffrey Leiden's experience overseeing the Knoll acquisition could make the exec a particularly attractive candidate in the current climate of increasing M&A activity
Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16